WSTQT69West Pharmaceutical Services, Inc.·NYSE
407.88-1.15%
News
Down 1.1% — What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call (marketbeat.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E45.78EPS (ttm)8.91Insider Own1.00%Shs Outstand70.38MPerf Week3.33%
Market Cap28.70BForward P/E39.82EPS next Y10.24Insider Trans-1.43%Shs Float69.85MPerf Month11.75%
Enterprise Value28.53BPEG4.04EPS next Q2.26Short Float2.88%Perf Quarter16.95%
Income639.00MP/S8.45EPS this Y32.56%Short Ratio3.28Perf Half Y35.88%
Sales3.40BP/B9.67EPS next Y8.90%ROA15.73%Short Interest2.01MPerf YTD48.24%
Book/sh42.17P/C61.86EPS next 5Y11.32%ROE21.08%52W High438.27 -6.93%Perf Year46.43%
Cash/sh6.59P/FCF63.37EPS past 3/5Y-4.18% 8.27%ROIC17.89%52W Low223.83 82.23%Perf 3Y24.61%
Dividend Est.1.04 (0.25%)EV/EBITDA29.47Sales past 3/5Y2.13% 7.44%Gross Margin37.59%Volatility3.14% 2.48%Perf 5Y-2.29%
Dividend TTM0.88 (0.22%)EV/Sales8.40EPS Y/Y TTM31.80%Oper. Margin22.97%ATR (14)10.39Perf 10Y469.03%
Dividend Ex-DateNov 10, 2026Quick Ratio2.10Sales Y/Y TTM12.60%Profit Margin18.81%RSI (14)69.43Recom2.24
Dividend Gr. 3/5Y5.20% 5.51%Current Ratio2.82EPS Q/Q35.71%SMA205.45%Beta1.11Target Price427.43
Payout9.83%Debt/Eq0.10Sales Q/Q8.83%SMA5010.63%Rel Volume2.48Prev Close412.62
Employees10,800LT Debt/Eq0.10EarningsFeb 11SMA20029.89%Avg Volume586.51KPrice407.88
IPO DateMar 17, 1980Option/ShortYes / YesEPS/Sales Surpr.20.87% 5.73%Net Debt/EBITDA-0.18Volume1,456,469Change-1.15%
Analyst Ratings
DateActionAnalystRatingTarget
Nov-02-26ReiteratedJefferiesBuy$295 → $475
Oct-07-26ReiteratedBarclaysOverweight$400 → $440
Sep-22-26UpgradeMorgan StanleyEqual Weight → Overweight$365 → $400
Sep-09-26ReiteratedUBSBuy$340 → $415
Jul-27-26ReiteratedEvercore ISI GroupOutperform$410 → $425
Jul-13-26InitiatedBNP ParibasOutperform$447
Jul-09-26ReiteratedMorgan StanleyEqual Weight$315 → $365
Jul-06-26ReiteratedEvercore ISI GroupOutperform$320 → $410
Jul-02-26ReiteratedKeybancOverweight$390
Jun-09-26UpgradeBarclaysEqual Weight → Overweight$310 → $400
Latest News· Times ET
Oct-31-26
Oct-29-26
Oct-28-26
Oct-27-26
Oct-21-26
Oct-19-26
Oct-19-2606:04PM
Oct-15-26
Oct-14-26
Company

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,3973,0742,8932,951—————
Cost of Goods Sold Incl. D&A2,1201,9701,8911,818—————
Gross Profit1,2761,1031,0021,133—————
Selling, General and Administrative Excl. Other438393339353—————
Research and Development76746968—————
Other Operating Expense-181901—————
Operating Income780617595711—————
Interest Expense0139—————
Unusual Expense
—————————
Non-Operating Income (Expense)13-1914—————
Net Income Before Taxes793615600716—————
Income Taxes168122108122—————
Consolidated Net Income639494493593—————
Net Income From Continuing Operations625494493593—————
Net Income639494493593—————
EPS (Recurring)8.976.836.757.99—————
EPS (Basic, Before Extraordinaries)8.976.836.757.99—————
EPS (Diluted)8.916.806.697.88—————
EBITDA968771744844—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio45.7840.4648.9644.69—————
Price To Sales Ratio8.406.448.278.83—————
Gross Margin37.5635.8834.6438.39—————
Operating Margin22.9620.0720.5724.09—————
Net Margin18.8116.0717.0420.09—————
Shares Outstanding70727374—————
Market Capitalization28,55219,81023,91226,057—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$444.53$384.17$323.81$263.45$203.09● Close Price0.00M0.88M1.76M2.64M3.52MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Favorite Annette FSr. VP & Chief HR OfficerSep 15 '26Sale365.002,524921,26021,818Sep 15
Favorite Annette FSr. VP & Chief HR OfficerSep 15 '26Option Exercise89.642,524226,25124,342Sep 15
Favorite Annette FSr. VP & Chief HR OfficerSep 14 '26Sale355.002,500887,50021,818Sep 15
Favorite Annette FSr. VP & Chief HR OfficerSep 14 '26Option Exercise89.642,500224,10024,318Sep 15
Favorite Annette FSr. VP & Chief HR OfficerSep 11 '26Sale345.002,500862,50021,818Sep 15
Favorite Annette FSr. VP & Chief HR OfficerSep 11 '26Option Exercise89.642,500224,1005,024Sep 15
Favorite Annette FSr. VP & Chief HR OfficerSep 08 '26Option Exercise85.378,135694,45319,663Sep 10
Favorite Annette FSr. VP & Chief HR OfficerSep 08 '26Sale340.812,500852,02516,845Sep 10
McMahon Robert W.SVP & Chief Financial OfficerAug 11 '26Option Exercise0.007,14909,784Aug 12
Campbell Shane AldenSVP, Proprietary SegmentMay 12 '26Option Exercise0.007700748May 14
Favorite Annette FSr. VP & Chief HR OfficerApr 27 '26Option Exercise83.472,817235,13519,645Apr 29
Favorite Annette FSr. VP & Chief HR OfficerApr 27 '26Sale305.202,817859,75316,828Apr 29
Winters ChadVP, Chief Accounting OfficerApr 27 '26Option Exercise173.22896155,2052,419Apr 29
Winters ChadVP, Chief Accounting OfficerApr 27 '26Sale300.67896269,3991,523Apr 29
Winters ChadVP, Chief Accounting OfficerFeb 20 '26Option Exercise0.008901,553Feb 23
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.